Page 333 - Read Online
P. 333

Page 10 of 12                            Flynn et al. J Cancer Metastasis Treat 2019;5:43  I  http://dx.doi.org/10.20517/2394-4722.2019.13

               Conflicts of interest
               All authors declare that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2019.


               REFERENCES
               1.   Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
               2.   O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005;10 Suppl 3:20-9.
               3.   Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice
                   guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii11-9.
               4.   Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
               5.   Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer
                   2014;14:611-22.
               6.   Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW. Metastasis-suppressor genes: a review and perspective on an emerging
                   field. J Natl Cancer Inst 2000;92:1717-30.
               7.   Cowin P, Welch DR. Breast cancer progression: controversies and consensus in the molecular mechanisms of metastasis and EMT. J
                   Mammary Gland Biol Neoplasia 2007;12:99-102.
               8.   Taylor DP, Wells JZ, Savol A, Chennubhotla C, Wells A. Modeling boundary conditions for balanced proliferation in metastatic latency.
                   Clin Cancer Res 2013;19:1063-70.
               9.   Wells A, Griffith L, Wells JZ, Taylor DP. The dormancy dilemma: quiescence versus balanced proliferation. Cancer Res 2013;73:3811-6.
               10.  Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic
                   sites. Cell 2012;150:764-79.
               11.  Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol
                   Cancer 2010;9:179.
               12.  Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, et al. Effect of inhibition of the lysophosphatidic acid receptor 1 on
                   metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst 2012;104:1306-19.
               13.  Klein CA. Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev 2011;21:42-9.
               14.  Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients
                   undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996;41:177-85.
               15.  Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol
                   2013;10:41-51.
               16.  Carcereri de Prati A, Butturini E, Rigo A, Oppici E, Rossin M, et al. Metastatic Breast Cancer Cells Enter Into Dormant State and Express
                   Cancer Stem Cells Phenotype Under Chronic Hypoxia. J Cell Biochem 2017;118:3237-48.
               17.  Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell
                   2009;137:1062-75.
               18.  Mowers EE, Sharifi MN, Macleod KF. Autophagy in cancer metastasis. Oncogene 2017;36:1619-30.
               19.  Prager BC, Xie Q, Bao S, Rich JN. Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell 2019;24:41-53.
               20.  Ding L, Ellis MJ, Li S, Larson DE, Chen K, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature
                   2010;464:999-1005.
               21.  Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, et al. Subclonal diversification of primary breast cancer revealed by
                   multiregion sequencing. Nat Med 2015;21:751-9.
               22.  Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide
                   resolution. Nature 2009;461:809-13.
               23.  Savas P, Teo ZL, Lefevre C, Flensburg C, Caramia F, et al. The subclonal architecture of metastatic breast cancer: results from a
                   prospective community-based rapid autopsy program "CASCADE". PLoS Med 2016;13:e1002204.
               24.  Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP. Downregulation of epithelial cadherin is required to initiate metastatic outgrowth
                   of breast cancer. Mol Bio cell 2011;22:2423-35.
               25.  Gooding AJ, Zhang B, Jahanbani FK, Gilmore HL, Chang JC, et al. The lncRNA BORG drives breast cancer metastasis and disease
                   recurrence. Sci Rep 2017;7:12698.
               26.  Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009;14:3-9.
               27.  Donnenberg VS, Meyer EM, Donnenberg AD. Measurement of multiple drug resistance transporter activity in putative cancer stem/
                   progenitor cells. Methods Mol Biol 2009;568:261-79.
   328   329   330   331   332   333   334   335   336   337   338